2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3066
    SKF 100398 77453-01-1 ≥98.0%
    SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP.
    SKF 100398
  • HY-P3072
    Mastoparan 17 145854-61-1 98.09%
    Mastoparan 17 is a tetradecapeptide. Mastoparan 17 is an inactive analogue of Mastoparan (HY-P0246) .
    Mastoparan 17
  • HY-P3153
    Cathepsin K 94716-09-3
    Cathepsin K is a cysteine protease with endo and collagenolytic activities. Cathepsin K induces degradation of bone collagen and can be used for the research of osteoporosis.
    Cathepsin K
  • HY-P3570
    Adipokinetic hormone II (Locusta migratoria) 98968-94-6 99.58%
    Adipokinetic hormone II (Locusta migratoria) (Lom-AKH-II) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs).
    Adipokinetic hormone II (Locusta migratoria)
  • HY-P3584
    (Pro3) GIP, human 299898-52-5 99.79%
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.
    (Pro3) GIP, human
  • HY-P3704
    Enterostatin (rat) 117137-85-6 98.16%
    Enterostatin (rat), an orally active activation peptide of procolipase, selectively reduces fat intake. Enterostatin (rat) reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism.
    Enterostatin (rat)
  • HY-P3899
    [Nle8] Somatostatin (1-28) 84768-30-9 98%
    [Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .
    [Nle8] Somatostatin (1-28)
  • HY-P4079
    hCT(18-32) 769175-01-1 99.84%
    hCT(18-32) is a hCT (human calcitonin)-derived peptide.
    hCT(18-32)
  • HY-P4195
    [K15,R16,L27]VIP(1-7)/GRF(8-27) 201995-58-6 98%
    [K15,R16,L27]VIP(1-7)/GRF(8-27), a VIP1 selective agonist, exhibits IC50 values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP1, rat VIP1, rat VIP2 receptors, respectively. VIP: VASOACTIVE Intestinal Polypeptide
    [K15,R16,L27]VIP(1-7)/GRF(8-27)
  • HY-P4373
    Hepcidin-1 (mouse) 1676104-75-8 98%
    Hepcidin-1 (mouse) is an endogenous peptide hormone involved in the regulation of iron homeostasis. Hepcidin-1 (mouse) upregulates mRNA levels of TRAP, cathepsin K, and MMP-9 and increases TRAP-5b protein secretion. Hepcidin-1 (mouse) downregulates the level of FPN1 protein and increases intracellular iron. Hepcidin-1 (mouse) facilitates osteoclast differentiation.
    Hepcidin-1 (mouse)
  • HY-P4701
    pTH-Related Protein (1-34) amide (human, mouse, rat) 112955-31-4 98%
    pTH-Related Protein (1-34) amide (human, mouse, rat) (Human PTHrP-(1-34)NH2) is a N-terminal fragments of PTHrP. pTH-Related Protein (1-34) amide (human, mouse, rat) induces hypercalcemia, and can be used for research of humoral hypercalcaemia of malignancy.
    pTH-Related Protein (1-34) amide (human, mouse, rat)
  • HY-P4805
    Peptide YY (13-36) (canine, mouse, porcine, rat) 86895-09-2 99.22%
    Peptide YY (13-36) (canine, mouse, porcine, rat) is a Y2 receptor subtype agonist.
    Peptide YY (13-36) (canine, mouse, porcine, rat)
  • HY-P5074
    GRPP (human) 1132745-52-8 98.94%
    GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets.
    GRPP (human)
  • HY-P5261
    SA1-III 2673230-58-3 99.28%
    SA1-III(KP1) is a bioactive peptide withanti-agingeffect and has been reported used as a cosmetic ingredient.
    SA1-III
  • HY-P5269
    Palmitoyl tetrapeptide-10 887140-79-6 99.46%
    Palmitoyl tetrapeptide-10 is a bioactive peptide. Palmitoyl tetrapeptide-10 works synergistically with other active ingredients to increase the expression of corneodesmosin (a marker of keratinocyte adhesion) and filaggrin (a marker of keratinocyte terminal differentiation), thereby reducing skin permeability and improving skin barrier function. Palmitoyl tetrapeptide-10 can be used in the research of sensitive skin syndrome and skin pigmentation.
    Palmitoyl tetrapeptide-10
  • HY-Z2667
    (R)-Esomeprazole 119141-89-8
    (R)-Esomeprazole ((R)-Omeprazole; (+)-Omeprazole) is an orally active cytochrome P450 2C19, CYP3A4, and CYP2C9-related metabolic modulator. (R)-Esomeprazole can be used in studies of digestive system diseases and compound metabolic interactions.
    (R)-Esomeprazole
  • HY-Z8033
    N-Desmethyl diltiazem hydrochloride 130606-60-9
    N-Desmethyl diltiazem hydrochloride is a substrate for CYP3A7 metabolism, which is the predominant fetal form and is minimally expressed in adults.
    N-Desmethyl diltiazem hydrochloride
  • HY-100144
    Pirozadil 54110-25-7 98.31%
    Pirozadil is a hypolipidemic agent.
    Pirozadil
  • HY-100240
    Lodelaben 111149-90-7
    Lodelaben is a human neutrophil elastase inhibitor with an IC50 and Ki of 0.5 and 1.5 μM, respectively.
    Lodelaben
  • HY-100304
    KW-8232 free base 170365-25-0
    KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232 free base
Cat. No. Product Name / Synonyms Application Reactivity